OnCo

Papillary carcinoma of the gallbladder: the decisions you may face

2 treatment settings, 0 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

Polypoid lesion of 10 mm or more on ultrasound

Described in words

Cholecystectomy under the joint European polyp guideline; pathology decides whether invasion is present.

The path, in plain words

This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.

Questions to ask about this decision
  1. Which specific treatments are you proposing for this setting, and what are the alternatives?
    Why: The standard of care here is described in words rather than named products; ask for the names.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. For my situation (polypoid lesion of 10 mm or more on ultrasound), which of the standard options do you recommend and why?
    Why: Guideline options include: Cholecystectomy under the joint European polyp guideline; pathology decides whether invasion is present.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Invasive papillary carcinoma

Described in words

Staged and treated as gallbladder adenocarcinoma by T category.

The path, in plain words

This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.

Questions to ask about this decision
  1. Which specific treatments are you proposing for this setting, and what are the alternatives?
    Why: The standard of care here is described in words rather than named products; ask for the names.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. For my situation (invasive papillary carcinoma), which of the standard options do you recommend and why?
    Why: Guideline options include: Staged and treated as gallbladder adenocarcinoma by T category.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.